Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Efficacy, Safety, and Pharmacokinetics of XP13512 (GSK1838262) in Patients With Restless Legs Syndrome
NCT01332305 is registered in ClinicalTrials.gov with XenoPort, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Efficacy, Safety, and Pharmacokinetics of XP13512 (GSK1838262) in Patients With Restless Legs Syndrome
- Lead sponsor
- XenoPort, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2007
- Completion date
- January 31, 2008
- Enrollment
- 217 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.